US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

XOMAO

XOMA (XOMAO)

XOMA Corporation

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XOMAO

Fecha	Hora	Fuente	Título	Símbolo	Compañía
20/06/2024	06:30	GlobeNewswire Inc.	XOMA Declares Quarterly Preferred Stock Dividends	NASDAQ:XOMAO	XOMA Corporation
12/06/2024	06:30	GlobeNewswire Inc.	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	NASDAQ:XOMAO	XOMA Corporation
14/05/2024	06:30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	NASDAQ:XOMAO	XOMA Corporation
09/05/2024	06:30	GlobeNewswire Inc.	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	NASDAQ:XOMAO	XOMA Corporation
30/04/2024	06:30	GlobeNewswire Inc.	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	NASDAQ:XOMAO	XOMA Corporation
25/04/2024	06:30	GlobeNewswire Inc.	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAO	XOMA Corporation
03/04/2024	08:00	GlobeNewswire Inc.	XOMA Corporation Announces Closing of Tender Offer	NASDAQ:XOMAO	XOMA Corporation
19/03/2024	15:05	GlobeNewswire Inc.	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	NASDAQ:XOMAO	XOMA Corporation
08/03/2024	06:30	GlobeNewswire Inc.	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAO	XOMA Corporation
28/02/2024	06:30	GlobeNewswire Inc.	XOMA to Present at Upcoming Investor Conferences in March	NASDAQ:XOMAO	XOMA Corporation
16/02/2024	07:00	GlobeNewswire Inc.	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	NASDAQ:XOMAO	XOMA Corporation
18/01/2024	07:30	GlobeNewswire Inc.	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	NASDAQ:XOMAO	XOMA Corporation
11/01/2024	15:05	GlobeNewswire Inc.	FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx	NASDAQ:XOMAO	XOMA Corporation
08/01/2024	06:30	GlobeNewswire Inc.	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	NASDAQ:XOMAO	XOMA Corporation
02/01/2024	06:30	GlobeNewswire Inc.	XOMA Announces Stock Repurchase Program of up to $50 Million	NASDAQ:XOMAO	XOMA Corporation
19/12/2023	06:30	GlobeNewswire Inc.	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties	NASDAQ:XOMAO	XOMA Corporation
07/11/2023	06:30	GlobeNewswire Inc.	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value	NASDAQ:XOMAO	XOMA Corporation
31/10/2023	06:30	GlobeNewswire Inc.	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	NASDAQ:XOMAO	XOMA Corporation
06/09/2023	06:30	GlobeNewswire Inc.	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:XOMAO	XOMA Corporation
08/08/2023	06:30	GlobeNewswire Inc.	XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy	NASDAQ:XOMAO	XOMA Corporation
23/06/2023	17:14	GlobeNewswire Inc.	XOMA Added to the Russell 2000® and Russell 3000® Indexes	NASDAQ:XOMAO	XOMA Corporation
22/06/2023	06:30	GlobeNewswire Inc.	XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset	NASDAQ:XOMAO	XOMA Corporation
25/05/2023	15:34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XOMAO	XOMA Corporation
18/05/2023	16:23	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:XOMAO	XOMA Corporation
09/05/2023	06:36	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XOMAO	XOMA Corporation
09/05/2023	06:30	GlobeNewswire Inc.	XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy	NASDAQ:XOMAO	XOMA Corporation
04/04/2023	15:20	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XOMAO	XOMA Corporation
09/03/2023	06:45	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XOMAO	XOMA Corporation
09/03/2023	06:30	GlobeNewswire Inc.	XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy	NASDAQ:XOMAO	XOMA Corporation
09/02/2023	11:47	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XOMAO	XOMA Corporation

Showing the most relevant articles for your search:NASDAQ:XOMAO

OMX Stockholm Household ...

Cognetivity Neurosciences

Nova Tech Enterprises (PK)

Veolia Environnement SA ...

China Treasures New Mate... (PK)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones